tirzepatide class of drugs Tirzepatide: A New Dual Receptor Agonist for Diabetes and Obesity | Sheshu kumar Gaddam posted on the topic Tirzepatide enhances weight loss with

Side Effects and Considerations While generally well-tolerated, possible side effects include: Mild water retention Redness or swelling at the injection site Occasional headaches or joint stiffness Women who are pregnant, breastfeeding, or have hormone-sensitive cancers should not use this peptide without physician approval

Our platform is designed to be a supportive home for your health journey

The problem is when we start looking to public insurance programs to cover them

Infections: vulvovaginal candidiasis, bacterial vaginosis, vulvovaginitis Comparative observational signal (protective association): In a phenome-wide association study comparing people with type 2 diabetes prescribed GLP-1 receptor agonists vs SGLT2 inhibitors and DPP4 inhibitors (NIH All of Us cohort, Jan 2018Oct 2023), semaglutide prescription was associated with reduced risk of diagnoses including candidiasis of vulva and vagina and inflammatory disease of cervix, vagina, and vulva compared with SGLT2 inhibitors

In June 2025, MBX Biosciences announced that it has submitted an IND application to the FDA for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug targeting obesity, which received regulatory clearance in July